Business Context and Reporting Period
Company: KKR Real Estate Finance Trust Inc. (KREF)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: KREF is a Maryland corporation operating as a mortgage REIT, focusing on originating and acquiring transitional senior loans secured by commercial real estate (CRE) assets. The company is externally managed by KKR Real Estate Finance Manager LLC.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Q4 2025 |
|---|---|---|---|
| Net Interest Income | $26.2 million | $31.3 million | $25.8 million |
| Total Other Income | $8.4 million | $3.9 million | $6.8 million |
| Provision for Credit Losses | $73.5 million | $24.9 million | $43.7 million |
| Net Loss Attributable to Common Stockholders | $(61.9) million | $(10.6) million | $(32.0) million |
| Net Loss Per Share (Basic & Diluted) | $(0.96) | $(0.15) | $(0.49) |
| Dividends Declared (Common) | $0.25 per share | $0.25 per share | $0.25 per share |
| Cash and Cash Equivalents | $135.4 million | $106.4 million | $84.6 million |
| Total Assets | $6.95 billion | N/A | $6.46 billion |
| Total Liabilities | $5.80 billion | N/A | $5.24 billion |
| Stockholders' Equity | $1.10 billion | N/A | $1.17 billion |
| Book Value Per Share | $11.87 | N/A | $13.04 |
Material Changes vs. Prior Periods
- Significant Increase in Credit Loss Provision: The provision for credit losses surged to $73.5 million in Q1 2026, a 196% increase year-over-year and a 68% increase from Q4 2025. This was primarily driven by additional reserves for risk-rated 5 office and life science loans.
- Net Loss Expansion: Net loss attributable to common stockholders widened to $(61.9) million compared to $(10.6) million in Q1 2025, largely due to the increased credit provision and a $17.3 million realized loss on a loan write-off.
- Portfolio Deterioration: The average risk rating of the loan portfolio increased to 3.3 (from 3.2 in Q4 2025). Risk-rated 5 loans now comprise 14% of the portfolio by outstanding principal, up from 11%.
- Foreign Currency Volatility: The company recorded a $5.4 million loss on foreign currency translation, partially offset by a $6.9 million gain on foreign currency forward contracts.
- Loan Portfolio Activity: Loan repayments ($489.7 million) significantly exceeded originations and fundings ($194.7 million), resulting in a net reduction in the loan portfolio size.
Guidance, Outlook, and Risks
- Management Commentary: Management highlighted significant volatility in global markets driven by inflation, elevated interest rates, and geopolitical tensions (specifically citing a conflict between the U.S., Israel, and Iran in February 2026). These conditions have adversely impacted commercial real estate values and transaction activity.
- Dividend Policy: The company maintained its quarterly common dividend at $0.25 per share despite the net loss. Distributable Earnings (a non-GAAP measure) were $(4.1) million for the quarter, or $(0.06) per share, compared to $14.4 million in Q4 2025.
- Liquidity Position: As of March 31, 2026, KREF held $135.4 million in cash and had $500.0 million of available capacity on its Revolver. The company maintains $535.0 million in unencumbered assets available for financing.
- Key Risks:
- Credit Risk: Deterioration in office and life science sectors, with four loans currently rated as "Impaired/Loss Likely" (Risk Rating 5).
- Interest Rate Risk: While rising rates generally increase net income, they may adversely affect borrower performance and collateral values.
- Financing Risk: 23% of financing is subject to credit mark-to-market provisions (repurchase agreements), which could trigger margin calls if asset values decline.
- Subsequent Events: In April 2026, the Board declared a Q2 2026 common dividend of $0.10 per share and authorized a new $75.0 million share repurchase program.
Investor Verification Checklist
- Credit Reserve Adequacy: Verify the specific collateral valuations and recovery assumptions for the four risk-rated 5 loans (Minneapolis Office, Boston Life Science, San Diego Multifamily, and Boston Life Science) that drove the $73.5 million provision.
- Loan Modification Impact: Review the terms of the Cambridge, MA life science loan modification, specifically the $17.3 million write-off of the subordinated note and the restructuring of the senior loan.
- Foreign Currency Exposure: Assess the effectiveness of the foreign currency forward contracts in hedging the GBP and EUR denominated assets, given the $5.4 million translation loss.
- Liquidity Covenants: Confirm compliance with the cash liquidity covenant (greater of $10 million or 5% of recourse indebtedness) and the interest coverage ratio (1.3 to 1.0) given the elevated interest expense.
- Real Estate Owned (REO) Disposition: Monitor the status of REO assets held for sale (Philadelphia Office and West Hollywood Condo) and the timeline for their disposition to recover capital.